Eric Fleekop
About Eric Fleekop
Eric Fleekop is Vice President, Deputy General Counsel at BioMarin Pharmaceutical Inc. and, following BioMarin’s acquisition of Inozyme, was appointed to Inozyme Pharma, Inc.’s board of directors and as the company’s Secretary effective July 1, 2025 . Inozyme became a wholly owned subsidiary of BioMarin and was delisted from Nasdaq on July 1, 2025, limiting public-company style disclosures for individual director/officer pay and performance going forward . As a post-merger appointee and subsidiary officer/director, TSR or EBITDA growth during his INZY “tenure” are not disclosed and are not meaningfully comparable due to the take-private context .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | Vice President, Deputy General Counsel | 2023–present | Senior legal leadership at parent; corporate and securities oversight . |
| BioMarin Pharmaceutical Inc. | Executive Director, Corporate Counsel – Corporate & Securities | Oct 2022–Mar 2023 | Corporate/securities counsel at public company . |
| BioMarin Pharmaceutical Inc. | Senior Director, Corporate Counsel – Corporate & Securities | Feb 2021–Oct 2022 | Corporate and securities legal work . |
| BioMarin Pharmaceutical Inc. | Director, Corporate Counsel – Corporate & Securities | Aug 2018–Feb 2021 | Corporate and securities legal work . |
| Incline Merger Sub, Inc. (BioMarin acquisition vehicle) | Secretary (Director of Purchaser) | 2025 | Officer role at tender-offer Purchaser in INZY acquisition . |
External Roles
| Organization | Role | Status | Notes |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | Vice President, Deputy General Counsel | Current | Parent-company role concurrent with INZY Secretary/director appointment . |
Board governance note: Effective July 1, 2025, he joined INZY’s board and was simultaneously appointed Secretary. The board post-close consists of BioMarin executives G. Eric Davis, Eric Fleekop, and Brian Mueller, indicating parent-controlled governance at the subsidiary .
Fixed Compensation
No Inozyme-specific cash compensation for Mr. Fleekop was disclosed in connection with his appointment as a post-merger subsidiary director/officer . For context only, pre-merger (public-company) non-employee director retainer levels were as follows (policy effective while INZY was public; not necessarily applicable after the BioMarin closing):
| Role | Member Annual Fee ($) | Chair Incremental Annual Fee ($) | Lead Independent Director ($) |
|---|---|---|---|
| Board of Directors | 40,000 | 30,000 | 60,000 |
| Audit Committee | 7,500 | 7,500 | — |
| Compensation Committee | 5,000 | 5,000 | — |
| Nominating & Corporate Governance | 4,000 | 4,000 | — |
| Research & Development | 4,000 | 4,000 | — |
Performance Compensation
There is no disclosure of any INZY-specific equity or cash incentive awards granted to Mr. Fleekop in his capacity as post-merger director/Secretary . For reference, the pre-merger, public-company non-employee director equity policy included stock options; this policy may not apply after the acquisition:
| Grant Type (pre-merger policy) | Amount | Vesting | Notes |
|---|---|---|---|
| Initial Option | 56,000 options | Monthly over 3 years | Exercise price at grant-date FMV; change-in-control full exercisability . |
| Annual Option | 28,000 options | Cliff on first anniversary or next annual meeting | Subject to continued service; issued at FMV . |
Equity Ownership & Alignment
- Post-merger capital structure: At closing, all INZY public shares were converted to $4.00 cash, and INZY became a wholly owned BioMarin subsidiary . Options with exercise prices below $4.00 became fully vested and were cashed out; options at or above $4.00 were cancelled; all RSUs fully vested and were cashed out at $4.00 per share .
- As a result, there is no ongoing INZY public equity ownership or pledging by any director/officer, and post-close insider selling pressure is not applicable (company is delisted and privately held by BioMarin) .
- Mr. Fleekop did not appear in the pre-merger April 28, 2025 beneficial ownership table (he was appointed after the Effective Time) .
| Equity Instrument | Treatment at Close | Economic Outcome |
|---|---|---|
| Common shares | Converted to $4.00 cash per share | Cash consideration to holders . |
| Stock options (strike < $4.00) | Accelerated vesting; cancelled for cash | Cash = (Shares x ($4.00 – strike)) . |
| Stock options (strike ≥ $4.00) | Cancelled | No payment . |
| RSUs | Accelerated vesting; cancelled for cash | Cash = (RSU shares x $4.00) . |
Form 4 monitoring: We searched for Form 4 filings associated with INZY directors/officers over the last 24 months and did not find Form 4s for Mr. Fleekop; note the company’s deregistration/delisting and post-merger subsidiary status meaning ongoing Section 16 reporting is not applicable . (Search summary: no Form 4s returned in our database query.)
Employment Terms
- Appointment mechanics and governance: Mr. Fleekop was appointed to the board and as Secretary effective immediately after the merger closing on July 1, 2025 .
- Indemnification and advancement: Post-close governing documents provide robust indemnification and advancement rights for directors and officers. The amended and restated certificate of incorporation provides exculpation for directors to the fullest extent permitted by Delaware law , and the bylaws include detailed indemnification and advancement provisions, enforcement rights, and insurance authorization for directors and officers .
- Compensation, severance, and change-of-control: No INZY-specific employment agreement, severance multiple, or change-of-control terms for Mr. Fleekop were disclosed in the 8-K appointing him . Company-wide treatment of equity at close is summarized above .
Board Service History, Committees, and Dual-Role Implications
- Service history: Appointed INZY director effective July 1, 2025 (post-close) .
- Committee roles: No committee assignments were disclosed in the July 1, 2025 8-K .
- Independence: Post-merger, INZY is a wholly owned subsidiary of BioMarin; the July 1, 2025 8-K does not designate independence status for new directors .
- Dual-role implications: Mr. Fleekop serves concurrently as an INZY director and as Secretary (an officer role) and is a senior legal executive at the parent, BioMarin, indicating governance and operational control aligned with the parent rather than independent oversight typical of a public board .
Investment Implications
- Alignment and trading signals: With INZY now a wholly owned BioMarin subsidiary and all public equity converted to cash, there is no ongoing INZY insider selling pressure or public market trading signal to interpret; incentives and retention considerations for Mr. Fleekop are principally tied to his BioMarin role, not to INZY-specific public equity .
- Governance/control: Board composition (three BioMarin executives) and Mr. Fleekop’s dual officer/director status underscore centralized control by BioMarin, typical for integrated subsidiaries; investor focus should shift to BioMarin’s strategic stewardship and legal/regulatory execution rather than standalone INZY governance .
- Contractual risk mitigants: Robust post-close indemnification and advancement provisions in INZY’s governing documents reduce personal liability risk for directors/officers, supporting retention of parent executives on the subsidiary board during integration and commercialization of INZ-701 under BioMarin’s umbrella .
Key disclosures leveraged: INZY 8-K (July 1, 2025) for board/officer appointments, delisting, and equity treatment ; Offer to Purchase Schedule I biographical details for Mr. Fleekop’s career roles at BioMarin and Purchaser ; 2025 DEF 14A for pre-merger director compensation policy (context only) ; INZY amended charter/bylaws for indemnification and governance mechanics .